|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-16.94/--
|
企业价值
40.63M
|
资产负债 |
每股账面净值
1.74
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
3.85
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/24 12:59 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS). |